Cipla Overview

  • Year Founded
  • 1935

Year Founded

  • Status
  • Public

  • Employees
  • 47,496

Employees

  • Stock Symbol
  • 500087

Stock Symbol

  • Investments
  • 39

  • Share Price
  • $15.15
  • (As of Thursday Closing)

Cipla General Information

Description

Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.

Contact Information

Website
www.cipla.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Cipla House, Peninsula Business Park
  • Ganpatrao Kadam Marg, Lower Parel
  • Mumbai, Maharashtra 400013
  • India
+91 022
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
BOM
Vertical(s)
Corporate Office
  • Cipla House, Peninsula Business Park
  • Ganpatrao Kadam Marg, Lower Parel
  • Mumbai, Maharashtra 400013
  • India
+91 022

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cipla Stock Performance

As of 19-Nov-2026, Cipla’s stock price is $15.15. Its current market cap is $12.2B with 808M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$15.15 $15.19 $12.58 - $17.34 $12.2B 808M 71.7K $0.39

Cipla Financials Summary

As of 30-Sep-2026, Cipla has a trailing 12-month revenue of $3.01B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 10,383,678 9,365,338 12,635,570 13,762,182
Revenue 3,006,115 3,136,093 3,210,299 3,073,790
EBITDA 550,414 695,822 898,312 784,560
Net Income 312,453 439,007 623,545 497,857
Total Assets 4,521,998 4,503,954 4,370,744 3,923,306
Total Debt 72,823 65,051 51,227 67,081
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cipla Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cipla‘s full profile, request access.

Request a free trial

Cipla Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product po
Pharmaceuticals
Mumbai, India
47,496 As of 2026

Ahmedabad, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cipla Competitors (49)

One of Cipla’s 49 competitors is Torrent Pharmaceuticals, a Corporation company based in Ahmedabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Torrent Pharmaceuticals Corporation Ahmedabad, India
Alkem Laboratories Formerly PE-Backed Mumbai, India
Glenmark Pharmaceuticals Corporation Mumbai, India
Mankind Pharma Formerly PE-Backed New Delhi, India
Lupin Corporation Mumbai, India
You’re viewing 5 of 49 competitors. Get the full list »

Cipla Patents

Cipla Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026176464-A1 Polymorphs of iptacopan hydrochloride Pending 21-Feb-2025
WO-2026159729-A1 Polymorphs of darolutamide Pending 24-Jan-2025
WO-2026159736-A1 Polymorphs of lorlatinib Pending 23-Jan-2025
WO-2026159600-A1 Composition for inhalation Pending 22-Jan-2025
WO-2026126223-A1 Polymorphs of trofinetide Pending 11-Dec-2024 C07D207/16
To view Cipla’s complete patent history, request access »

Cipla Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cipla Investments & Acquisitions (39)

Cipla’s most recent deal was a Merger/Acquisition with Inzpera Healthsciences for . The deal was made on 04-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Inzpera Healthsciences 04-Dec-2025 Merger/Acquisition Internet Retail
Cipla (Jiangsu) Pharmaceuticals 25-Oct-2024 Secondary Transaction - Private Pharmaceuticals
Sahajanand Medical Technologies 15-Oct-2024 Merger/Acquisition Surgical Devices
GoApptiv 01-Oct-2024 Later Stage VC Enterprise Systems (Healthcare)
Ethris 18-Jun-2024 Later Stage VC Drug Discovery
You’re viewing 5 of 39 investments and acquisitions. Get the full list »

Cipla ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

25.05 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Cipla’s complete esg history, request access »

Cipla Exits (8)

Cipla’s most recent exit was on 15-Jun-2023 from Wellthy Therapeutics. The exit was categorized as with 18 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Wellthy Therapeutics 15-Jun-2023 Completed
  • 18 buyers
Wellthy Therapeutics 09-Mar-2019 Completed
  • 6 buyers
Anmarate 12-Apr-2017 Completed
Quality Chemical Industries 22-May-2015 Completed
Saba Investment 01-Jan-2014 Merger/Acquisition Completed
  • 2 buyers
You’re viewing 5 of 8 exits. Get the full list »

Cipla Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Cipla (Jiangsu) Pharmaceuticals China 2019
Inzpera Healthsciences Mumbai, India 2016
Cipla New Ventures Mumbai, India 2013
Cipla Medpro South Africa Century, South Africa 1935
Cipla EU Addlestone, United Kingdom

Cipla FAQs

  • When was Cipla founded?

    Cipla was founded in 1935.

  • Where is Cipla headquartered?

    Cipla is headquartered in Mumbai, India.

  • What is the size of Cipla?

    Cipla has 47,496 total employees.

  • What industry is Cipla in?

    Cipla’s primary industry is Pharmaceuticals.

  • Is Cipla a private or public company?

    Cipla is a Public company.

  • What is Cipla’s stock symbol?

    The ticker symbol for Cipla is 500087.

  • What is the current stock price of Cipla?

    As of 19-Nov-2026 the stock price of Cipla is $15.15.

  • What is the current market cap of Cipla?

    The current market capitalization of Cipla is $12.2B.

  • What is Cipla’s current revenue?

    The trailing twelve month revenue for Cipla is $3.01B.

  • Who are Cipla’s competitors?

    Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals, Mankind Pharma, and Lupin are some of the 49 competitors of Cipla.

  • What is Cipla’s annual earnings per share (EPS)?

    Cipla’s EPS for 12 months was $0.39.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process